List view / Grid view
28 September 2015 | By Victoria White
A 24-year, Phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer can safely take HRT during or after their treatment.
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
6 August 2015 | By Victoria White
NICE has opened a second consultation on preliminary draft guidance on olaparib for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
24 July 2015 | By Victoria White
A study of more than 30,000 women shows that aromatase inhibitors substantially reduce the risk of death in postmenopausal women ER-positive breast cancer...
2 June 2015 | By Victoria White
Draft guidance issued by NICE on the drug olaparib do not recommend its use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
19 May 2015 | By Victoria White
Clinicians aiming to compare the use of proton therapy in the treatment of medulloblastoma with conventional photon radiotherapy...
5 May 2015 | By Victoria White
A patient has become the first to receive a new ‘resistance-busting’ panRAF inhibitor with the launch of a phase I clinical trial...
9 April 2015 | By Victoria White
Genetic screening could improve doctors’ ability to work out which women are at increased risk of developing breast cancer, a major study has shown...
10 February 2015 | By The Institute of Cancer Research
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “We’re very disappointed that Scottish men with prostate cancer will miss out on the chance to have abiraterone much earlier in their course of treatment as a result of this decision..."
5 November 2014 | By The Institute of Cancer Research, London
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert has said...
27 October 2014 | By The Institute of Cancer Research
The European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA mutation - the first time a cancer drug has been approved targeted at an inherited genetic fault...
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
23 September 2014 | By The Institute of Cancer Research
Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports...
15 September 2014 | By The Institute of Cancer Research, London
Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease...
